Page 32 - TD-4-1

Tumor Discovery Immunohistochemistry profiling of ovarian cysts

43. Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan 54. Hartenbach EM, Olson AT, Goswitz JJ, et al. Vascular
NC. New predictive biomarkers for ovarian cancer. endothelial growth factor (VEGF) expression and survival
Diagnostics (Basel). 2021;11(3):465. in human epithelial ovarian carcinomas. Cancer Lett.
1997;121(2):169-175.
doi: 10.3390/diagnostics11030465
doi: 10.1016/S0304-3835(97)00425-8
44. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery
and characterization of glycosylated eosinophil-derived 55. James NE, Chichester C, Ribeiro JR. Beyond the biomarker:
neurotoxin and COOH-terminal osteopontin fragments for Understanding the diverse roles of human epididymis
ovarian cancer in urine. Clin Cancer Res. 2006;12(2):432-441. protein 4 in the pathogenesis of epithelial ovarian cancer.
doi: 10.1158/1078-0432.CCR-05-1406 Front Oncol. 2018;8:124.
45. Singer G, Oldt R 3 , Cohen Y, et al. Mutations in BRAF and doi: 10.3389/fonc.2018.00124
rd
KRAS characterize the development of low-grade ovarian 56. Drapkin R, Von Horsten HH, Lin Y, et al. Human
serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-486. epididymis protein 4 (HE4) Is a secreted glycoprotein
doi: 10.1093/jnci/95.6.484 that is overexpressed by serous and endometrioid ovarian
carcinomas. Cancer Res. 2005;65(6):2162-2169.
46. Schummer M, Ng WV, Bumgarner RE, et al. Comparative
hybridization of an array of 21 500 ovarian cDNAs for the doi: 10.1158/0008-5472.CAN-04-3812
discovery of genes overexpressed in ovarian carcinomas. 57. Li XH, Chen XJ, Ou WB, et al. Knockdown of creatine
Gene. 1999;238(2):375-385. kinase B inhibits ovarian cancer progression by decreasing
doi: 10.1016/S0378-1119(99)00379-4 glycolysis. Int J Biochem Cell Biol. 2013;45(5):979-986.
47. Konstantinopoulos PA, Lheureux S, Moore KN. PARP doi: 10.1016/j.biocel.2013.01.015
inhibitors for ovarian cancer: Current indications, future 58. Huddleston HG, Wong K, Welch WR, Berkowitz RS,
combinations, and novel assets in development to target Mok SC. Clinical applications of microarray technology:
DNA damage repair. Am Soc Clin Oncol Educ Book. Creatine kinase B is an up-regulated gene in epithelial
2020;40:e116-e131. ovarian cancer and shows promise as a serum marker.
doi: 10.1200/EDBK_292956 Gynecol Oncol. 2005;96(1):77-83.
48. Kobayashi M, Sawada K, Kimura T. Potential of integrin doi: 10.1016/j.ygyno.2004.08.041
inhibitors for treating ovarian cancer: A literature review. 59. Tamir A, Gangadharan A, Balwani S, et al. The serine
Cancers (Basel). 2017;9(7):83. protease prostasin (PRSS8) is a potential biomarker for early
doi: 10.3390/cancers9010008 detection of ovarian cancer. J Ovarian Res. 2016;9(1):1-13.
49. Luo LY, Katsaros D, Scorilas A, et al. Prognostic value doi: 10.1186/s13048-016-0215-5
of human kallikrein 10 expression in epithelial ovarian 60. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum
carcinoma. Clin Cancer Res. 2001;7(8):2372-2379. marker for ovarian cancer: Identification through microarray
50. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in technology. J Natl Cancer Inst. 2001;93(19):1458-1464.
metastatic lesions as a prognostic marker in ovarian cancers. doi: 10.1093/jnci/93.19.1458
J Biomed Sci. 2007;14(3):373-381.
61. McIntosh MW, Drescher C, Karlan B, et al. Combining CA
doi: 10.1007/s11373-006-9136-0 125 and SMR serum markers for diagnosis and early detection
51. Brakora K, Lee H, Yusuf R, et al. Utility of osteopontin as of ovarian carcinoma. Gynecol Oncol. 2004;95(1):9-15.
a biomarker in recurrent epithelial ovarian cancer. Gynecol doi: 10.1016/j.ygyno.2004.07.039
Oncol. 2004;93(2):361-365.
62. Chang K, Pastan I. Molecular cloning of mesothelin,
doi: 10.1016/j.ygyno.2003.12.026 a differentiation antigen present on mesothelium,
52. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S
Terao, T. Upregulation of bikunin in tumor-infiltrating A. 1996;93(1):136-140.
macrophages as a factor of favorable prognosis in ovarian doi: 10.1073/pnas.93.1.136
cancer. Gynecol Oncol. 2004;94(3):725-734.
63. Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in
doi: 10.1016/j.ygyno.2004.04.013
epithelial ovarian carcinoma: A new screening marker and
53. Matsuzaki H, Kobayashi H, Yagyu T, et al. Plasma bikunin as prognostic factor. Anticancer Res. 2006;26(6B):4721-4728.
a favorable prognostic factor in ovarian cancer. J Clin Oncol. 64. Zheng X, Chen S, Li L, et al. Evaluation of HE4 and TTR
2005;23(7):1463-1472.
for diagnosis of ovarian cancer: Comparison with CA-125.
doi: 10.1200/JCO.2005.04.112 J Gynecol Obstet Hum Reprod. 2018;47(6):227-230.

Volume 4 Issue 1 (2025) 24 doi: 10.36922/td.5369